TY - JOUR
T1 - Novel therapies for heart failure
T2 - vasopressin and selective aldosterone antagonists.
AU - Kamath, Sandeep A.
AU - Laskar, S. Raja
AU - Yancy, Clyde W.
PY - 2005
Y1 - 2005
N2 - Despite favorable improvements in mortality, heart failure (HF) remains a problematic illness due to the ever-present burden of hospitalization. Clearly, novel treatment strategies are needed. This review focuses on two newer pharmacologic targets: arginine vasopressin and aldosterone. Arginine vasopressin receptor antagonists will most likely serve as an adjunct to or replacement of standard diuretic therapy in selected patients. The safety and efficacy of chronic therapy with oral arginine vasopressin receptor antagonists in large groups of congestive HF patients is currently under investigation. Aldosterone antagonism is emerging as a treatment of severe congestive HF. Recent large-scale clinical trials using aldosterone antagonists have proven that those with HF or left ventricular dysfunction postmyocardial infarction derive a survival benefit from aldosterone antagonism. Whether aldosterone antagonism should be prescribed in all patients with HF is unclear; however, in carefully selected and managed patients, aldosterone antagonism is helpful.
AB - Despite favorable improvements in mortality, heart failure (HF) remains a problematic illness due to the ever-present burden of hospitalization. Clearly, novel treatment strategies are needed. This review focuses on two newer pharmacologic targets: arginine vasopressin and aldosterone. Arginine vasopressin receptor antagonists will most likely serve as an adjunct to or replacement of standard diuretic therapy in selected patients. The safety and efficacy of chronic therapy with oral arginine vasopressin receptor antagonists in large groups of congestive HF patients is currently under investigation. Aldosterone antagonism is emerging as a treatment of severe congestive HF. Recent large-scale clinical trials using aldosterone antagonists have proven that those with HF or left ventricular dysfunction postmyocardial infarction derive a survival benefit from aldosterone antagonism. Whether aldosterone antagonism should be prescribed in all patients with HF is unclear; however, in carefully selected and managed patients, aldosterone antagonism is helpful.
UR - http://www.scopus.com/inward/record.url?scp=18244368747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244368747&partnerID=8YFLogxK
U2 - 10.1111/j.1527-5299.2005.03912.x
DO - 10.1111/j.1527-5299.2005.03912.x
M3 - Review article
C2 - 15722667
AN - SCOPUS:18244368747
SN - 1527-5299
VL - 11
SP - 21
EP - 29
JO - Congestive heart failure (Greenwich, Conn.)
JF - Congestive heart failure (Greenwich, Conn.)
IS - 1
ER -